Credit Suisse Hikes TESARO Target Price to $122 On Robust Niraparib Data; Shares Up

Credit Suisse reiterated its Outperform rating on TESARO Inc TSRO and raised its price target to $122 from $90 to reflect the potential M&A thesis. Excluding M&A, the discounted cash flow-based target remains at $90.

Waltham, Massachusetts-based TESARO has an approved product in Varubi (rolapitant) for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. The company is also developing its Phase 3 asset, niraparib, a PARP inhibitor in ovarian and breast cancer indications.

Tesaro said it would file NDA and MAA for all patients with recurrent, platinum-sensitive ovarian cancer in the fourth quarter 2016.

Related Link: Citi Sees 26% Upside In TESARO On The Strength Of Trial Data

Further, the brokerage said the recent ESMO conference shows Niraparib has broad effects across the second-line ovarian cancer population and expects the labeling to likewise be broad.

On the M&A front, the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily) given high demand for late stage oncology assets, especially in the PARP space due to its potential for activity across a range of tumors.

"Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0 percent POS for now but we conservatively see at least another $1 billion in sales from PARP expansion," analyst Alethia Young wrote in a note.

"For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50–75 percent and R&D synergies of 15–30 percent. In our base case TSRO P&L we model a tax rate of 30 percent so there could be synergies here as well," Young added.

Young also sees further upside to valuation in the long-term from:

    1. "PARP expansion in other platinum sensitive tumors."
    2. "Potential HRD- sales in 1L as we expect the company will amend the protocol."
    3. "Readouts in breast cancer PARP studies in '17."
    4. "Immuno-oncology where we expect early data over 2017."

At the time of writing, shares of Tesaro had surged 22.58 percent on the day to $121.69 after setting a new 52-week high of $118.80.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechLong IdeasNewsHealth CarePrice TargetReiterationM&AAnalyst RatingsMoversTrading IdeasGeneralAlethia YoungCredit SuisseRolapitantVarubi
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!